On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer, of Hepion Pharmaceuticals, Inc. provided notice to the Company of his resignation as CMO, effective September 29, 2023. Dr. Hobbs? resignation is not associated with, or attributable to, any disagreement with the Company or the Company?s operations, policies, or practices.

On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company?s current Chairman of the Company?s Scientific Advisory Board, as Consultant Medical Director. Dr. Harrison previously served as the Company?s Consultant Medical Director from October 2019 until February 2021. He is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.

He is internationally known for studies in NAFLD/NASH (particularly drug development) with over 300 peer reviewed publications and an H Index of 101. Dr. Harrison currently serves as the founder and chairman for both Pinnacle Clinical Research and Summit Clinical Research (an internationally recognized integrated research organization with over 100 sites worldwide) in San Antonio, Texas. He is the lead Principal Investigator for numerous NASH development programs.